Turkey says COVID-19 vaccine from China's Sinovac 91.25% effective

ANKARA (Reuters) - A COVID-19 vaccine developed by China's Sinovac Biotech is 91.25% effective according to preliminary data from a late-stage study in Turkey. This is possibly a much better result than from a separate study with the vaccine in Brazil.
Researchers in Brazil, who are also conducting a final Phase III study of the vaccine, said the shot was more than 50% effective on Wednesday but withheld the full results at the company's request and asked questions about transparency.
Turkish researchers said Thursday that no major side effects were noted during their study, apart from one person who had an allergic reaction.
Scroll to continue with the content
Microsoft and Redis
Meet the fast and fully managed in-memory data store.
Don't miss the opportunity to hear the unique perspectives from Microsoft and partner specialists and learn more about Azure Cache for Redis.
The Turkish trial began on September 14, and researchers said 1,322 people participated.
Sinovac is the first Chinese vaccine company to release details from late-stage clinical trials after positive results from competing products from Pfizer, Moderna and AstraZeneca last month.
The Turkish researchers, who spoke with Health Minister Fahrettin Koca, said 26 of the 29 people infected during the study were given placebos. The study would continue until 40 people were infected.
"We are now sure that the vaccine is effective and safe (to use) in Turks," said Koca, adding that Ankara would use the data to license the vaccine.
Turkey had agreed to buy 50 million cans of Sinovacs shot and receive delivery by December 11, but shipping was delayed.
Koca said the doses would arrive on Monday, adding that Turkey would vaccinate about nine million people in the first group, starting with health workers.
Sinovac also has supply contracts for its vaccine called CoronaVac with countries like Indonesia, Brazil, Chile and Singapore, and is negotiating with the Philippines and Malaysia.
Koca also said Turkey will sign an agreement with Pfizer and its partner BioNTech to supply 4.5 million doses of their vaccine by the end of March, with the option to purchase an additional 30 million doses later.
(Reporting by Tuvan Gumrukcu and Ali Kucukgocmen; Additional reporting by Roxanne Liu; Editing by Alex Richardson and Mark Potter)

You should check here to buy the best price guaranteed products.

Last News

First Casualty by Toby Harnden review: this is Afghanistan's Black Hawk Down

Boat captain who lost everything to Ida dedicates his time to helping others

South Dakota man recycles his collection of a million aluminum cans to raise $105K for Make-A-Wish

Trump pushed back when Lindsey Graham asked him to 'repair the damage' with Pence after January 6 riot: book

Minnesota police group says a man claiming to be Derek Chauvin's bodyguard 'never spent one minute' with him

Kyrie Irving Addresses Rumor He Would Retire If Traded by Nets